SCHEMBL1442007

SCHEMBL1442007

CCc1cc2c(O)nc(Sc3cccnc3)nc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNK O75909 1/20 0.37
CDK12 Q9NYV4 1/20 0.37
DHFR P00374 2/20 0.35
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
TYMS P04818 1/20 0.34
DAO P14920 2/20 0.33
HPGD P15428 2/20 0.33
GFER P55789 1/20 0.33
PARP1 P09874 1/20 0.33
PDPK1 O15530 1/20 0.32
ALDH1A1 P00352 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31
KDM5A P29375 1/20 0.31
VCP P55072 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1441697 0.86 CCNK (0.35) CCNKCDK12DHFRNOS3NOS1
SCHEMBL10316629 0.77 ADORA1 (0.31)
SCHEMBL10316653 0.75 HRH4 (0.41) DHFRDAOHPGDGFERALDH1A1
SCHEMBL18484200 0.75 NUDT1 (0.43) CCNKCDK12AURKBTYMSDAO
SCHEMBL1442302 0.72 ENPP1 (0.31)
SCHEMBL12819625 0.69 ADORA1 (0.33) PARP1
SCHEMBL14820369 0.67 TYMS (0.41) DHFRTYMSHPGDGFER
SCHEMBL10316635 0.67 NOS3 (0.32) NOS3NOS1NOS2TYMS
SCHEMBL14819978 0.66 TYMS (0.40) DHFRTYMSHPGDGFER
SCHEMBL1443430 0.66 HRH4 (0.41) HPGDGFERALDH1A1NPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037059-A1 GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-09 US disclosed
US-9481675-B2 Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-01 US disclosed
US-20130079323-A1 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2013-03-28 US disclosed
EP-2475666-A2 GYRASE INHIBITORS Trius Therapeutics, Inc. (US) 2012-07-18 EP disclosed
WO-2011032050-A2 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037059-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B CCNK 731/4885CDK12 1698/4885DHFR 561/4885
US-20130079323-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B CCNK 731/4885CDK12 1698/4885DHFR 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.